Fresenius Kabi launches two generic drugs in the U.S.

Fresenius Kabi today announced the immediate availability of two drugs in the United States. The first product, Gadobutrol Injection, a gadolinium-based contrast agent for used in MRIs.¹ It is the latest addition to Fresenius Kabi’s new radiology portfolio that offers hospitals a range of cost-effective contrast agents. The second product, Plerixafor Injection, a hematopoietic stem cell mobilizer is the newest addition to the company’s large generic injectable oncology medicine portfolio. 

¹ Gadobutrol Injection Package Insert, January 2023